Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 676 to 690 of 1974 results for nice guidelines

  1. Who can register as a stakeholder?

    Find out more about the types of organisations that can register to be a stakeholder at NICE.

  2. Who can register as a stakeholder?

    Find out more about the types of organisations that can register to be a stakeholder at NICE.

  3. Guidance on the use of electroconvulsive therapy (TA59)

    Evidence-based recommendations on electroconvulsive therapy (ECT) for treating catatonia, prolonged or severe manic episodes or schizophrenia in adults.

  4. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  5. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  6. News, blogs and podcasts

    to get new medicines up to 6 months sooner A new aligned pathway between NICE and the Medicines and Healthcare products Regulatory...

  7. Subscribe to our GP reference panel

    Subscribe to our GP reference panel and contribute to the development of NICE guidance in a quick and easy way.

  8. Ivabradine for treating chronic heart failure (TA267)

    Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure in adults.

  9. Freelite assays for diagnosing multiple myeloma and related conditions (terminated assessment) (HTG619)

    NICE no longer plans to develop guidance on Freelite assays for diagnosing multiple myeloma and related conditions in primary care.

    Sections for HTG619

  10. Cenobamate for treating focal onset seizures in epilepsy (TA753)

    Evidence-based recommendations on cenobamate (Ontozry) for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines.

  11. Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)

    Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.

  12. Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)

    Evidence-based recommendations on ruxolitinib (Jakavi). This drug is for adults with disease-related splenomegaly or symptoms caused by primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only if they have intermediate-2 or high-risk disease.

  13. Into practice resources

    Resources, case studies and patient decision aids to show how you can use evidence to improve care and services

  14. NICE and virtual wards

    We're working with colleagues to ensure that virtual wards are used in a way that maximises the value for patients and the NHS.